Volanesorsen sodium
Based on 1 Customer Validation
Volanesorsen (ISIS 304801) sodium is an antisense oligonucleotide inhibitor of apolipoprotein CIII (apo-CIII) mRNA that reduces triglyceride levels and improves insulin resistance. Volanesorsen sodium is being studied in the treatment of hypertriglyceridemia, familial chylosiderosis syndrome, and type 2 diabetes.
For research use only. We do not sell to patients.
- Purity: 98.51%
- CAS No.: 1573402-50-2
- Formula: C230H301N63Na19O125P19S19
- Molecular Weight:7165 (free acid)
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
|
apoC3 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Chow-Fed Cynomolgus[1]
-
Dosage:4, 8, 12 and 40 mg/kg
-
Administration:Subcutaneous injection (s.c.) Once a week for 13 weeks
-
Result:Reduced apoC-III mRNA by 47%, 51%, 80%, and 89% in a dose-responsive manner.
-
Animal Model:Rhesus monkeys with hypertriglyceridemia after taking high fructose supplements[1]
-
Dosage:10 mg/kg
-
Administration:Subcutaneous injection (s.c.) Once a week for 10 weeks
-
Result:Reduced plasma triglycerides, very low–density lipoprotein (VLDL)+chylomicron triglyceride, and decreased postprandial triglyceride excursion, while increasing high-density lipoprotein-cholesterol (HDL-C) in hypertriglyceridemic rhesus monkeys.
Chemical Information
-
CAS No. 1573402-50-2
-
Appearance Solid
-
Molecular Weight 7165 (free acid)
-
Formula C230H301N63Na19O125P19S19
-
Color White to off-white
-
SMILES
[Volanesorsen (sodium)]
-
Synonyms
ISIS 304801 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479-1490. [Content Brief]
[2]. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371(23):2200-2206. [Content Brief]
[3]. Post N, Yu R, Greenlee S, et al. Metabolism and Disposition of Volanesorsen, a 2'-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019;47(10):1164-1173. [Content Brief]
[4]. Lightbourne M, et al. Volanesorsen, an Antisense Oligonucleotide to Apolipoprotein-CIII, Decreases Triglycerides and Increases Lipoprotein Lipase Activity in Partial Lipodystrophy. Journal of the Endocrine Society, 2021, 5(Supplement_1): A305-A305. [Content Brief]
[5]. Paik J, et al. Volanesorsen: first global approval. Drugs, 2019, 79(12): 1349-1354. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)